|
Jul 1
|
RCKT's IND for RP-A701 in Dilated Cardiomyopathy Gets FDA Clearance
|
|
Jul 1
|
Rocket Pharmaceuticals receives FDA clearance of RP-A701
|
|
Jun 30
|
Rocket Pharmaceuticals Announces FDA IND Clearance of RP-A701 for the Treatment of BAG3-associated Dilated Cardiomyopathy
|
|
Jun 20
|
Gene Therapy Was the Biggest Idea in Biotech. Now It Has Lost Support on Wall Street.
|
|
May 9
|
RCKT's Q1 Loss Narrower Than Expected, Pipeline in Focus
|
|
May 8
|
Rocket Pharmaceuticals: Q1 Earnings Snapshot
|
|
May 8
|
Rocket Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Progress
|
|
Mar 2
|
When Will Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Turn A Profit?
|
|
Feb 28
|
Rocket Pharmaceuticals Q4 Loss Narrower Than Estimates, Pipeline in Focus
|
|
Feb 27
|
Rocket Pharmaceuticals: Q4 Earnings Snapshot
|
|
Feb 27
|
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress
|
|
Jan 2
|
Rocket Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
|
|
Dec 31
|
Wedbush starts Rocket Pharmaceuticals with Outperform into ‘inflection year’
|
|
Dec 30
|
Rocket Pharmaceuticals' Continued Pipeline Development to Support Long-Term Growth Potential, Wedbush Says
|
|
Dec 29
|
Rocket Pharmaceuticals, Inc. (RCKT): Is This Gene Therapy Stock a Good Buy Right Now?
|
|
Sep 10
|
Rocket Pharmaceuticals Announces Appointment of Mikael Dolsten, M.D., Ph.D., to Board of Directors
|
|
Sep 9
|
Rocket Stock Down More Than 30% in Past Six Months: Here's Why
|
|
Aug 25
|
Morgan Stanley Predicts up to 220% Jump for These 2 ‘Strong Buy’ Stocks
|
|
May 10
|
Rocket Pharmaceuticals Presents Positive Data from LV Hematology Portfolio at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
|
|
May 7
|
Rocket's (RCKT) Q1 Loss Narrower Than Expected, Sales Nil
|